Pregabalin Capsule
Product Images NDC 70518-3646

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 70518-3646). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Pregabalin 300 mg oral capsules packaging label by RemedyRepack Inc. The label states 60 capsules per bottle, with the labeler listed as RemedyRepack Inc. It includes regulatory and handling information such as the control schedule (C-V), storage temperature instructions, and manufacturing details by Ascend Labs, LLC, Montvale, NJ.*

FDA Label Image

Pregabalin-equation (Pregabalin Equation)

A text panel showing a formula for calculating creatinine clearance (CLCr). The formula includes variables for age (years), weight (kg), serum creatinine (mg/dL), and a multiplication factor of 0.85 for female patients.*

FDA Label Image

Pregabalin-figure-6 (Pregabalin Figure 6)

A bar chart comparing responder rates (%) for Pregabalin capsules at various dosages versus placebo in two studies labeled Study E1 and Study E3. Doses range from 50 mg/day, 150 mg/day, 300 mg/day, to 600 mg/day with BID and TID administration. The chart highlights statistically significant increases compared to placebo at multiple dose levels.*

FDA Label Image

Pregabalin-figure-7 (Pregabalin Figure 7)

A line graph depicting seizure reduction as median percentage change from baseline versus dose (mg/day) in multiple studies of pregabalin. The graph includes Study E1 BID (circles), Study E2 TID (squares), Study E3 BID (triangles), and Study E3 TID (open triangles) with statistical significance values shown for each dose compared to placebo, highlighting dose-dependent seizure reduction.*

FDA Label Image

Study Dpn 1 (Pregabalin Image 1)

A line graph depicting the relationship between percent improvement in pain from baseline (horizontal axis) and percent of patients improved (vertical axis) for Pregabalin at doses of 200 mg, 300 mg, 600 mg three times a day, and placebo. The graph compares multiple treatment groups with varying efficacy levels.*

FDA Label Image

Study Sci 1 (Pregabalin Image 10)

A line graph comparing the percent of subjects improved over a range of percent improvement from baseline to Week 12 using a measure labeled BOCF. Two groups are shown: Pregabalin and Placebo, with the Pregabalin group generally showing a higher percentage of subjects improved across the improvement range.*

FDA Label Image

Pain Intensity-study Sci 2 (Pregabalin Image 11)

A line graph comparing the percentage of subjects improved over time from baseline to Week 16, showing two lines representing Pregabalin and Placebo. The x-axis indicates the percent improved, and the y-axis indicates the percent of subjects improved, illustrating higher improvement rates in the Pregabalin group compared to Placebo.*

FDA Label Image

Study Dpn 2 (Pregabalin Image 2)

A line chart showing the percent of patients improved versus percent improvement in pain from baseline. Two lines compare Pregabalin 100 mg three times a day and placebo, illustrating relative effectiveness across different pain improvement thresholds.*

FDA Label Image

Study Phn 1 (Pregabalin Image 3)

Line graph depicting percent of patients improved versus percent improvement in pain from baseline. It compares Pregabalin at doses of 300 mg, 150 mg, and 75 mg taken twice a day against placebo over a range of pain improvement percentages. The vertical axis represents percent of patients improved, and the horizontal axis measures percent improvement in pain from baseline.*

FDA Label Image

Study Phn 2 (Pregabalin Image 4)

A line graph comparing the percentage of patients improved against the percent improvement in pain from baseline for Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The graph shows trends for each treatment group across various levels of pain improvement.*

FDA Label Image

Study Phn 3 (Pregabalin Image 5)

A line graph displaying the percent of patients improved versus percent improvement in pain from baseline. It compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo, showing trends of pain improvement across different levels of percentage improvement.*

FDA Label Image

Fibromyalgia Study F1 (Pregabalin Image 8)

A line graph showing percent of patients improved plotted against percent improvement in pain from baseline. It compares four groups: Pregabalin 600 mg daily dose, Pregabalin 450 mg daily dose, Pregabalin 300 mg daily dose, and placebo. Lines indicate differences in patient improvement across varying degrees of pain relief.*

FDA Label Image

Fibromyalgia Study F2 (Pregabalin Image 9)

A line graph depicting the estimated percentage of subjects without LTR (loss to remission) over 180 days. The graph compares two groups: one treated with Pregabalin and a placebo group. The vertical axis shows the percentage of subjects without LTR, ranging from 0% to 100%. The horizontal axis represents days from 0 to 180. Pregabalin shows a higher percentage of subjects without LTR compared to placebo throughout the study period.*

FDA Label Image

Pregabalin Structure (Pregabalin Srtuc 1)

Chemical structure of pregabalin, showing its molecular framework with a carboxylic acid (CO2H) group and an amino (NH2) group attached to a branched carbon chain.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.